Palisade Bio receives Canadian patent for inflammatory bowel drug

Palisade Bio has been granted a Canadian patent for its innovative drug aimed at treating inflammatory bowel disease. This development is significant as it not only strengthens the company's intellectual property portfolio but also enhances the potential for bringing a much-needed treatment to patients suffering from this chronic condition. With the increasing prevalence of inflammatory bowel diseases, this patent could pave the way for new therapeutic options and improve the quality of life for many.